Group 1 - The board of directors of Megachip New Materials Technology (Shanghai) Co., Ltd. held its 16th meeting on August 20, 2025, with all 9 directors present [1][2] - The board approved several proposals, including adjustments to the use of temporarily idle funds for purchasing financial management products, increasing the limit from RMB 600 million to RMB 1.05 billion [2][3] - The company plans to distribute a cash dividend of RMB 0.68 per share (including tax) to all shareholders, excluding treasury stock [3][4] Group 2 - The board's decisions will be submitted for approval at the company's third extraordinary general meeting of shareholders in 2025 [2][3] - The company will change the implementation method of the "Marketing and Service Network Construction Project" without altering the total amount of raised funds [3] - A special verification opinion was issued by UBS Securities Co., Ltd. regarding the changes in the investment structure [3]

Summary of Key Points Core Viewpoint The report outlines the fundraising and usage status of Hubei Xingfu Electronic Materials Co., Ltd. for the first half of 2025, detailing the amount raised, its allocation, and management practices to ensure compliance with regulatory requirements. Group 1: Fundraising Overview - The total net amount raised from the initial public offering (IPO) was RMB 1,071.0444 million, confirmed by an audit report issued on January 17, 2025 [1]. - As of June 30, 2025, the company directly invested RMB 362.9329 million into fundraising projects, with RMB 700 million remaining in cash management [1][2]. - The balance in the fundraising special account was RMB 13.9987 million, which includes unspent issuance costs of RMB 3.7547 million [1][2]. Group 2: Fund Management Practices - The company has established a special account storage system for fundraising, ensuring compliance with relevant laws and regulations [1]. - A tripartite supervision agreement was signed with the underwriter and banks to clarify rights and obligations regarding the management of the raised funds [1][2]. Group 3: Actual Usage of Funds - The company approved the use of RMB 198.9372 million to replace self-funded investments in fundraising projects and RMB 120.651 million for issuance costs [2][4]. - No idle funds were used to temporarily supplement working capital during the reporting period [2][5]. - The company has not used any excess funds for permanent working capital or loan repayment [5][6]. Group 4: Project Adjustments - The company decided to terminate the "Electronic Chemical Research Center Construction Project" and reallocate the funds to the "40,000 tons/year Ultra-Pure Electronic Chemicals Project (Shanghai)" [4][6]. - The total investment for the "40,000 tons/year Ultra-Pure Electronic Chemicals Project (Shanghai)" was adjusted from RMB 570.9905 million to RMB 793.3827 million [6][7]. Group 5: Compliance and Reporting - The company has adhered to regulations regarding the use and disclosure of fundraising, with no violations reported [4][5]. - The report includes a detailed comparison of the actual usage of funds against planned allocations, confirming that all disclosures were timely and accurate [4][5].

Core Points - The company has approved the addition of its wholly-owned subsidiary, Shanghai Biyimi Electronics Technology Co., Ltd., as the implementation entity for the fundraising project "Development and Industrialization of Power Management Series Control Chips" [3][7] - The fundraising project will now be implemented in Shanghai, optimizing resource allocation and improving the efficiency of fund usage [3][7] - The total amount raised from the initial public offering (IPO) was RMB 95,201.58 million, with a net amount of RMB 86,077.79 million after deducting issuance costs [2][3] Fundraising Overview - The company issued 17,262,300 shares at a price of RMB 55.15 per share during its IPO [2] - The total investment amount for the fundraising projects is RMB 65,251.50 million [2] - The "Biyimi R&D Center Construction Project" has been completed and is now operational [2] New Implementation Entity and Location - The original implementation entities for the project were the company and Hangzhou Biyimi Electronics Co., Ltd. [3] - The new implementation entity is Shanghai Biyimi Electronics Technology Co., Ltd., and the new location is Shanghai [3][5] - The changes do not affect the investment direction, total investment, or implementation content of the fundraising projects [3][7] Regulatory Compliance - The company will supervise the use of raised funds in accordance with relevant regulations and has established a dedicated fund account for this purpose [6][8] - The supervisory board and the sponsor have expressed their agreement with the changes, confirming compliance with legal and regulatory requirements [8][9]

Group 1 - The company Zhejiang Huayuan Biopharmaceutical Co., Ltd. has issued convertible bonds to unspecified investors, with a total amount of RMB 1.2 billion [2][3] - The bonds have a maturity of 6 years, with an annual interest rate that increases from 0.3% in the first year to 2.5% in the sixth year [4][5] - The initial conversion price for the bonds is set at RMB 15.19 per share, subject to adjustments based on various corporate actions [5][6] Group 2 - The funds raised from the bond issuance will be used for projects including the production of 6,000 tons of Vitamin A powder and 20,000 tons of Vitamin E powder, with a total investment of RMB 134.446 million [12][13] - The company plans to adjust the use of raised funds, reallocating some towards a new project for producing 1 billion solid dosage forms and 8 million injections, with a total investment of RMB 19.11 million [22][23] - The project aims to enhance the company's R&D and production capabilities, addressing the growing demand for high-quality pharmaceuticals in various therapeutic areas [23][24] Group 3 - The company has faced increased competition in the generic drug market, prompting a strategic shift in its investment focus [21][24] - The new project is expected to improve the company's production efficiency and meet international quality standards, ultimately benefiting patients [23][25] - The project is aligned with national policies promoting the development of innovative pharmaceuticals and aims to strengthen the company's market position [26][27]

Core Viewpoint - Haichuang Pharmaceutical announced adjustments to certain sub-projects within its "Innovative Drug R&D Project" to enhance the efficiency of fundraising, while keeping the total investment amount unchanged [2]. Group 1 - The company will hold its second board meeting and the tenth supervisory board meeting on August 13, 2025, to review the proposal for adjustments [2]. - The adjustments to the fundraising projects require approval from the company's shareholders' meeting [2].

Core Viewpoint - Zhejiang Tiantian Technology Co., Ltd. has decided to terminate the construction projects for the production lines of rubber vibration damping pads and steel rail waveguide vibration absorbers, reallocating the remaining raised funds of 325 million yuan to supplement working capital for daily operations [1][4]. Group 1: Project Termination - The company believes that continuing the projects may face risks of not meeting expected investment returns, and has considered overall development plans to improve fund utilization efficiency and protect shareholder interests [1][4]. - The projects that are being terminated include the annual production line of 400,000 square meters of rubber vibration damping pads and the annual production line of 450,000 steel rail waveguide vibration absorbers [1]. Group 2: Financial Performance - In 2024, the company achieved an operating income of 2.136 billion yuan, a year-on-year increase of 41.69%, and a net profit attributable to shareholders of 15.2042 million yuan, recovering from a loss of 654 million yuan in the previous year [4]. - However, in the first quarter of 2025, the company reported total operating revenue of 358 million yuan, a year-on-year decrease of 39.92%, and a net profit attributable to the parent company of 10.2598 million yuan, down 45.60% year-on-year [4]. - The decline in revenue is primarily attributed to delays in engineering construction progress, resulting in unrecognized income [4].

Core Viewpoint - The company has approved an internal adjustment of the investment structure for its fundraising project related to the construction of a key component production base for new energy vehicles, without changing the total investment amount or the total amount of raised funds [1][4]. Fundraising Basic Situation - The company issued 5.5 million convertible bonds at a face value of RMB 100 each, raising a total of RMB 550 million. After deducting issuance costs of RMB 7.605 million, the net amount raised was RMB 542.395 million, which has been deposited into a special account [1][2]. Fundraising Project Basic Situation - The total investment for the new energy vehicle key component production base construction project is RMB 710.38 million, with RMB 542.39 million allocated from the raised funds [3]. Adjustment of Investment Structure - The company plans to adjust the internal investment structure of the "new energy vehicle key component production base construction project," specifically reallocating funds from "working capital" to "machinery and equipment purchase and installation costs," while keeping the total investment and the amount of raised funds unchanged [3][4]. Reasons for Adjustment - The adjustment is made to optimize processes and meet the increasing demands for efficiency and space in the rapidly developing new energy vehicle industry, ensuring the project aligns with actual needs and accelerates construction [4]. Impact of Adjustment - The adjustment does not change the total investment or the total amount of raised funds, and it is aimed at optimizing resource allocation and supporting the company's strategic development, ensuring no adverse effects on normal operations [4][5]. Review Procedures and Opinions - The adjustment was reviewed and approved in meetings of the board of directors and the supervisory board, and it does not require shareholder approval. Both the supervisory board and the sponsor institution have expressed their agreement with the decision, confirming compliance with relevant regulations [5][6].

证券代码：301380 证券简称：挖金客 公告编号：2025-047 北京挖金客信息科技股份有限公司 该议案尚需提交公司股东大会审议。 具体内容详见公司同日披露于巨潮资讯网（http://www.cninfo.com.cn）上的 《关于部分募投项目结项并将节余募集资金用于其他募投项目、调整募投项目内 部投资结构及募投项目延期的公告》（公告编号：2025-044）。 根据《公司法》《上市公司章程指引》等法律法规的相关规定，结合公司实 际情况，公司拟取消监事会，监事会的职权由董事会审计委员会行使，《监事会 议事规则》等涉及监事会的相关制度将同步进行废止、修订。 本公司及监事会全体成员保证信息披露内容的真实、准确和完整，没有虚假 记载、误导性陈述或重大遗漏。 一、监事会会议召开情况 北京挖金客信息科技股份有限公司（以下简称"公司"）第四届监事会第二 次会议于2025年8月12日以现场方式召开，会议通知于2025年8月2日以书面、电 子邮件、电话等方式发出。本次会议由监事会主席韩陆先生主持，应参会监事3 名，实际参会监事3名。会议的召集、召开符合《公司法》相关法律法规及《公 司章程》的规定。 二、监事会审议情况 调整 ...

Core Viewpoint - The company plans to adjust the investment construction progress of certain fundraising projects, specifically postponing the expected operational date of the "Composite External Insulation Product Expansion Project (Phase I)" from August 2025 to December 31, 2025, and will conclude the "Digital Factory Construction Project for Composite Crossarms" [1][2][13]. Fundraising Project Adjustments - The company will transfer the surplus fundraising amount of 11.894 million yuan (after deducting bank fees) to the "Composite External Insulation Product Expansion Project (Phase I)" [1][11]. - The total amount raised from the non-public offering in 2020 was approximately 424 million yuan, with a net amount of about 418 million yuan after deducting issuance costs [2][4]. Project Status and Financial Management - As of July 31, 2025, the "Composite External Insulation Product Expansion Project (Phase I)" has completed the process route verification and design, equipment selection, and partial equipment procurement and installation [8][9]. - The company has effectively managed idle fundraising by investing in financial products, generating additional income [11][12]. Board Decisions and Compliance - The adjustments were approved in the board meeting held on August 12, 2025, and do not require shareholder approval as they do not alter the project implementation entity, fundraising purposes, or investment scale [12][13]. - The sponsor, Huatai United Securities, has confirmed that the adjustments comply with relevant regulations and will not adversely affect the company's operations or shareholder interests [12][14].

华泰联合证券有限责任公司关于 江苏神马电力股份有限公司 调整部分募投项目投资建设进度暨部分募投项目结项并将 节余募集资金用于其他募投项目的核查意见 华泰联合证券有限责任公司（以下简称"华泰联合证券"或"保荐人"）作 为江苏神马电力股份有限公司（以下简称"神马电力"或"公司"）2020 年非公 开发行股票的保荐人，根据《证券发行上市保荐业务管理办法》《上市公司募集 资金监管规则》《上海证券交易所上市公司自律监管指引第 1 号——规范运作》 等相关法律法规和规范性文件的规定，对公司调整部分募投项目投资建设进度暨 部分募投项目结项并将节余募集资金用于其他募投项目进行了认真、审慎的核查， 并发表意见如下： 一、募集资金基本情况 经中国证券监督管理委员会《关于核准江苏神马电力股份有限公司非公开发 行股票的批复》（证监许可[2021]346 号），公司非公开发行 32,218,837 股，每 股发行价格为人民币 13.16 元，共计募集资金人民币 423,999,894.92 元，扣除相 关发行费用 5,716,837.75 元（不含税）后，非公开发行实际募集资金净额为人民 币 418,283,057.17 元。 上述募 ...